PanelSure | NGS >> Women Focused Panel >> Hereditary Breast and Ovarian Cancer Syndrome : Seq Panel

Hereditary Breast and Ovarian Cancer Syndrome : Seq Panel

Sidebar Image
Condition Description Indications
Detection Specimen Requirements

 

Condition Description        

Mutations in the genes BRCA1 and BRCA2 cause hereditary breast and ovarian cancer syndrome (HBOC), an autosomal dominant cancer predisposition syndrome.  Mutations in these genes are rare and account for only a small percentage of cancers; about 5-10% of all breast cancers and 10-15% of ovarian cancers are due to mutations in the BRCA1 or BRCA2 genes. Individuals with mutations in these genes, however, are at a significantly increased risk for developing breast, ovarian, and other cancers than those in the general population.

In families with HBOC syndrome, there is typically a pattern of early onset breast cancer (before the age of 50 or pre-menopausal). Additionally, the family history may show more than one primary breast cancer in an individual, breast cancer in two or more generations, breast cancer in a male relative, and ovarian cancer, with or without a breast cancer diagnosis.

Females with a BRCA1 mutation have a 50-85% risk of developing breast cancer and up to a 44% risk of developing ovarian cancer. Females with a BRCA2 mutation have a 40-70% risk of developing breast cancer and up to a 27% risk of developing ovarian cancer. Males with a BRCA1 or BRCA2 mutation can have up to a 5-10% lifetime risk for male breast cancer and an elevated risk of prostate cancer.  Additionally, both males and females with BRCA1 or BRCA2 mutations may be at elevated risks for other cancers. Individuals with a mutation in the BRCA1 or BRCA2 gene have a 50% risk of passing on the mutation to their children.

Genes                                                                                                                                                 

BRCA1, BRCA2

Indications

This test is indicated for:

Confirmation of a clinical diagnosis of HBOC.

Carrier testing in adults with a family history of HBOC.

Methodology                                                                                                                                      

Next Generation Sequencing: In-solution hybridization of all coding exons is performed on the patient’s genomic DNA. Although some deep intronic regions may also be analyzed, this assay is not meant to interrogate most promoter regions, deep intronic regions, or other regulatory elements, and does not detect single or multi-exon deletions or duplication. Direct sequencing of the captured regions is performed using next generation sequencing. The patient's gene sequences are then compared to a standard reference sequence. Potentially causative variants and areas of low coverage are Sanger-sequenced. Sequence variations are classified as pathogenic, likely pathogenic, benign, likely benign, or variants of unknown significance. Variants of unknown significance may require further studies of the patient and/or family members.

Please note that a "backbone" of probes across the entire genome are included on the array for analytical and quality control purposes. Rarely, off- target copy number variants causative of disease may be identified that may or may not be related to the patient's phenotype. Only known pathogenic off-target copy number variants will be reported. Off-target copy number variants of unknown clinical significance will not be reported.

Detection                                                                                                                                            

Next Generation Sequencing: Clinical Sensitivity: Unknown. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions/duplications will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient's clinical/biochemical phenotype.

Analytical Sensitivity:~99%.

Specimen Requirements                                                                                                                     

Submit only 1 of the following specimen types

* Preferred specimen type: Whole Blood in Yellow Cap

Type: EDTA Whole Blood; Adults: 5-10 ml.

Isolated DNA: In microtainer (20-30 ug high Quality Genomic DNA, shipped at 2-4 oC). Isolation using the QiagenTM  Puregene kit for DNA extraction is recommended.

Specimen Collection and Shipping: Refrigerate until time of shipment. Ship sample within 5 days of collection at room temperature with overnight delivery.